^
    Back
    Association details:
    Biomarker:HER-2 negative
    Cancer:HER2 Negative Breast Cancer
    Drug:albumin-bound paclitaxel (Bcl2 inhibitor, Tubulin inhibitor) +
    cyclophosphamide (Alkylating agent) +
    epirubicin (Topoisomerase II inhibitor) +
    Neulasta (pegfilgrastim) (G-CSF stimulant)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Jpn J Clin Oncol
    Title:

    Efficacy and safety of dose-dense neoadjuvant chemotherapy with nab-paclitaxel followed by epirubicin and cyclophosphamide for operable breast cancer

    Published date:
    08/22/2023
    Excerpt:
    Patients with histologically confirmed stage I-III HER2-negative breast cancer were enrolled in this study. Patients received nanoparticle albumin-bound paclitaxel (260 mg/m2) followed by epirubicin (90 mg/m2) and cyclophosphamide (600 mg/m2) every 2 weeks with pegfilgrastim....Among the 55 patients enrolled in this study, 13 (23.6%) achieved pathological complete response, of whom 10/26 (38.5%) patients had triple-negative disease and 3/29 (10.3%) had luminal disease. The objective response was observed in 46 (83.6%) patients.
    DOI:
    10.1093/jjco/hyad112